Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
United States: 1-888-708-7444 or 1-919-852-4685
France: +33 1 56 95 17 10
Germany: +49 89 45 10 300
United Kingdom: +44 (0) 114 292 2322
India: +91 984 500 6625
Interested in Certara's biosimulation solutions? Want to speak to someone in our sales team? Click on the link below!
The drug label is the culmination of years of work and millions, if not billions of dollars. Every inclusion and exclusion on that label will have a direct impact on the drug’s profitability.
While biosimulation has been an important element in drug development for some time, its impact over the past 18 months with regard to label optimization has been profound. Specifically, F.D.A’s acceptance of Physiologically-Based Pharmacokinetic PBPK modeling and simulation has impacted key label elements in more than fifteen cases, driving down R&D costs and timelines, and allowing for greater population inclusion within the label.
Certara has been at the forefront of this evolution, working with sponsor companies and regulators to prove that modeling and simulation can deliver the return on investment. From guiding clinical study designs with smaller and more precise trials to the waiving of studies, including drug-drug interactions (DDI) and special populations, Certara’s label optimization services provide unquestionable value. These services comprise both mechanistic modeling (bottom up) and pharmacokinetic-pharmacodynamic PK/PD modeling (top down), along with regulatory consulting focused on guiding regulatory interactions around optimizing your drug label.
Click here to Learn more: